Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 50, 2012, Pages 20467-20472

  Bursać, Sladana ^a   Brdovčak, Maja Cokarić ^a   Pfannkuchen, Martin ^a,b   Orsolić, Ines ^a   Golomb, Lior ^c   Zhu, Yan ^d   Katz, Chen ^d   Daftuar, Lilyn ^d   Grabusǐć, Kristina ^a,e   Vukelić, Iva ^a   Filić, Vedrana ^a   Oren, Moshe ^c   Prives, Carol ^d   Volarević, Sinisǎ ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d Howard Hughes Medical Institute   (United States)

^e Centre for High throughput Technologies Radmile Matej i 2   (Croatia)

Author keywords

Proteasome; Ribosomal stress

Indexed keywords

DACTINOMYCIN; DNA DIRECTED RNA POLYMERASE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME; PROTEIN MDM2; PROTEIN P53; RIBOSOMAL PROTEIN L11; RIBOSOMAL PROTEIN L5; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOGENESIS; CELL DISRUPTION; CELL FRACTIONATION; CELL STRESS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; RIBOSOME; RIBSOME BIOGENESIS;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL NUCLEOLUS; DACTINOMYCIN; HUMANS; MICE; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; RIBOSOMAL PROTEINS; RIBOSOMES; RNA, MESSENGER; RNA, SMALL INTERFERING; STRESS, PHYSIOLOGICAL; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84870908454     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1218535109     Document Type: Article

References (39)

1. Vousden KH, Prives C (2009) Blinded by the light: The growing complexity of p53. Cell 137(3):413-431.
2. Zilfou JT, Lowe SW (2009) Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 1(5):a001883.
3. Robles AI, Harris CC (2010) Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2(3):a001016.
4. Volarevic S, et al. (2000) Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science 288(5473):2045-2047. (Pubitemid 30397685)
5. Sulic S, et al. (2005) Inactivation of S6 ribosomal protein gene in T lymphocytes activates a p53-dependent checkpoint response. Genes Dev 19(24):3070-3082. (Pubitemid 41798121)
6. Zhang Y, Lu H (2009) Signaling to p53: Ribosomal proteins find their way. Cancer Cell 16(5):369-377.
7. Golomb L, et al. (2012) Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell 45(2):222-232.
8. Jones NC, et al. (2008) Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. Nat Med 14(2):125-133. (Pubitemid 351214559)
9. Barkić M, et al. (2009) The p53 tumor suppressor causes congenital malformations in Rpl24-deficient mice and promotes their survival. Mol Cell Biol 29(10):2489-2504.
10. Pellagatti A, et al. (2010) Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. Blood 115(13):2721-2723.
11. Fumagalli S, Thomas G (2011) The role of p53 in ribosomopathies. Semin Hematol 48 (2):97-105.
12. Dai MS, Lu H (2004) Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 279(43):44475-44482.
13. Bhat KP, Itahana K, Jin A, Zhang Y (2004) Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J 23(12):2402-2412. (Pubitemid 38954847)
14. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH (2003) Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3(6):577-587. (Pubitemid 36808652)
15. Zhang Y, et al. (2003) Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 23 (23):8902-8912. (Pubitemid 37433388)
16. Dai MS, et al. (2004) Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 24(17):7654-7668.
17. Jin A, Itahana K, O'Keefe K, Zhang Y (2004) Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 24(17):7669-7680. (Pubitemid 39121492)
18. Zhang Y, et al. (2010) Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26. Nucleic Acids Res 38(19):6544-6554.
19. Chen D, et al. (2007) Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: Binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene 26(35):5029-5037. (Pubitemid 47206956)
20. Zhu Y, et al. (2009) Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell 35(3):316-326.
21. Horn HF, Vousden KH (2008) Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway. Oncogene 27(44):5774-5784.
22. Fumagalli S, et al. (2009) Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol 11(4):501-508.
23. Fumagalli S, Ivanenkov VV, Teng T, Thomas G (2012) Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. Genes Dev 26(10):1028-1040.
24. Lapik YR, Fernandes CJ, Lau LF, Pestov DG (2004) Physical and functional interaction between Pes1 and Bop1 in mammalian ribosome biogenesis. Mol Cell 15(1):17-29. (Pubitemid 38850216)
25. Robledo S, et al. (2008) The role of human ribosomal proteins in the maturation of rRNA and ribosome production. RNA 14(9):1918-1929.
26. Andersen JS, et al. (2002) Directed proteomic analysis of the human nucleolus. Curr Biol 12(1):1-11.
27. Cohen AA, et al. (2008) Dynamic proteomics of individual cancer cells in response to a drug. Science 322(5907):1511-1516.
28. Volarević S, Thomas G (2001) Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 65:101-127.
29. Warner JR (1977) In the absence of ribosomal RNA synthesis, the ribosomal proteins of HeLa cells are synthesized normally and degraded rapidly. J Mol Biol 115(3):315-333.
30. Lam YW, Lamond AI, Mann M, Andersen JS (2007) Analysis of nucleolar protein dynamics reveals the nuclear degradation of ribosomal proteins. Curr Biol 17(9):749-760. (Pubitemid 46635118)
31. Andersen JS, et al. (2005) Nucleolar proteome dynamics. Nature 433(7021):77-83. (Pubitemid 40101146)
32. Sundqvist A, Liu G, Mirsaliotis A, Xirodimas DP (2009) Regulation of nucleolar signalling to p53 through NEDDylation of L11. EMBO Rep 10(10):1132-1139.
33. Tsvetkov P, Reuven N, Shaul Y (2009) The nanny model for IDPs. Nat Chem Biol 5(11):778-781.
34. Condemine W, Takahashi Y, Le Bras M, de Thé H (2007) A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells. J Cell Sci 120(Pt 18):3219-3227. (Pubitemid 350018413)
35. Ito A, et al. (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20(6):1331-1340. (Pubitemid 32233973)
36. Bernardi R, et al. (2004) PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6(7):665-672. (Pubitemid 38960925)
37. Macias E, et al. (2010) An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell 18(3):231-243.
38. Donati G, et al. (2011) The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells. Oncogene 30(29):3274-3288.
39. Marechal V, Elenbaas B, Piette J, Nicolas JC, Levine AJ (1994) The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol 14(11):7414-7420. (Pubitemid 24326406)